Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Combination Lexapro and Massage for Treatment of Depression in Older Adults

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2008-03-26
Last Posted Date
2019-06-18
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
17
Registration Number
NCT00643162
Locations
🇺🇸

Cedars-Sinai Medical Center Department of Psychiatry and Behavioral Neurosciences, Los Angeles, California, United States

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

First Posted Date
2008-03-25
Last Posted Date
2019-07-26
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
29
Registration Number
NCT00642694
Locations
🇺🇸

University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

Escitalopram Treatment of Night Eating Syndrome

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-03-14
Last Posted Date
2016-06-29
Lead Sponsor
Duke University
Target Recruit Count
40
Registration Number
NCT00636649
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

Saint Louis University, St. Louis, Missouri, United States

Brain Mechanisms and Targeting Insomnia in Major Depression

First Posted Date
2008-03-05
Last Posted Date
2010-08-20
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
60
Registration Number
NCT00628914
Locations
🇺🇸

Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California, United States

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

First Posted Date
2008-02-22
Last Posted Date
2014-02-04
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
26
Registration Number
NCT00621946
Locations
🇺🇸

The UT Southwestern Medical Center at Dallas, Dallas, Texas, United States

Behavioral Insomnia Therapy For Those With Insomnia and Depression

First Posted Date
2008-02-22
Last Posted Date
2013-05-31
Lead Sponsor
Toronto Metropolitan University
Target Recruit Count
477
Registration Number
NCT00620789
Locations
🇨🇦

Ryerson University, Toronto, Ontario, Canada

ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-02-12
Last Posted Date
2010-06-30
Lead Sponsor
Inje University
Target Recruit Count
35
Registration Number
NCT00613067
Locations
🇰🇷

Psychiatry department, Inje Univ. Ilsanpaik Hospital, Goyang, Kyunggi, Korea, Republic of

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-02-08
Last Posted Date
2013-05-31
Lead Sponsor
Duke University
Target Recruit Count
15
Registration Number
NCT00610506
Locations
🇺🇸

Dept Psychiatry, Duke University Medical Center, Durham, North Carolina, United States

Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

First Posted Date
2008-01-28
Last Posted Date
2016-08-25
Lead Sponsor
Veterans Medical Research Foundation
Target Recruit Count
73
Registration Number
NCT00601965
Locations
🇺🇸

UCSD Outpatient Psychiatric Services, San Diego, California, United States

🇺🇸

Washington University, St. Louis, Missouri, United States

🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy

Not Applicable
Conditions
Interventions
First Posted Date
2008-01-18
Last Posted Date
2008-04-01
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
40
Registration Number
NCT00598052
Locations
🇮🇱

Sourasky Medical Center, Tel Aviv, Israel

© Copyright 2024. All Rights Reserved by MedPath